Key Points
- Director Briggs Morrison bought 20,000 shares on March 6 at an average price of $13.40 (~$268,000), increasing his direct stake to 96,021 shares — a 26.31% rise.
- Arvinas posted a weak quarter with EPS of $(1.10) vs. consensus $(0.55) and revenue of $9.5M vs. $37.26M (down 84% y/y); the stock trades near $13.37 with a market cap of about $855M and a 52‑week range of $5.90–$18.45.
- Large institutions have been adding positions (e.g., Millennium Management +885,483 shares), leaving 95.19% institutional ownership, while analysts are mixed — consensus rating "Hold" with a $13.65 average price target.
Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) Director Briggs Morrison acquired 20,000 shares of the firm's stock in a transaction that occurred on Friday, March 6th. The stock was bought at an average cost of $13.40 per share, with a total value of $268,000.00. Following the completion of the transaction, the director directly owned 96,021 shares in the company, valued at $1,286,681.40. The trade was a 26.31% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Arvinas Trading Down 1.7%
Shares of Arvinas stock opened at $13.37 on Tuesday. The firm's 50 day simple moving average is $12.64 and its two-hundred day simple moving average is $10.92. The firm has a market capitalization of $855.15 million, a price-to-earnings ratio of -10.45 and a beta of 1.87. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $18.45.
Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. During the same quarter in the previous year, the firm posted ($0.63) earnings per share. The company's quarterly revenue was down 84.0% on a year-over-year basis. On average, sell-side analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
ARVN has been the topic of several research reports. Barclays increased their price target on shares of Arvinas from $16.00 to $18.00 and gave the stock an "overweight" rating in a report on Wednesday, December 17th. Citigroup boosted their target price on shares of Arvinas from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Thursday, March 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arvinas in a research report on Monday, December 22nd. Wedbush boosted their price objective on Arvinas from $9.00 to $11.00 and gave the company a "neutral" rating in a report on Tuesday, February 24th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $20.00 target price (up from $16.00) on shares of Arvinas in a report on Wednesday, February 25th. Ten analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Arvinas presently has an average rating of "Hold" and a consensus price target of $13.65.
Read Our Latest Research Report on Arvinas
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new stake in shares of Arvinas during the 1st quarter worth about $727,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Arvinas in the 1st quarter valued at about $301,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Arvinas by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,636 shares of the company's stock valued at $271,000 after purchasing an additional 2,122 shares in the last quarter. Millennium Management LLC raised its holdings in Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company's stock worth $9,198,000 after purchasing an additional 885,483 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Arvinas by 108.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 902,925 shares of the company's stock worth $6,339,000 after purchasing an additional 469,394 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.
Arvinas Company Profile
(
Get Free Report)
Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.
The company's most advanced clinical candidates address hormone-driven cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
